ALIROCUMAB vs Inclisiran

#111 Clinical Trials updated on 2021-07-28 All 111 studies in this list are **actively recruiting** at one or more locations. Most studies in this list **accept healthy volunteers** with the exception of any studies missing a 'Y' in the Healthy Volunteers column. Those studies may or may not be ac

#102 Clinical Trials updated on 2021-07-27 All 102 studies in this list are **actively recruiting** at one or more locations. Most studies in this list **accept healthy volunteers** with the exception of any studies missing a 'Y' in the Healthy Volunteers column. Those studies may or may not be ac

#54 Clinical Trials updated on 2021-07-19 All 54 studies in this list are **actively recruiting** at one or more locations. Most studies in this list **accept healthy volunteers** with the exception of any studies missing a 'Y' in the Healthy Volunteers column. Those studies may or may not be acce

#136 Clinical Trials updated on 2021-07-23 All 136 studies in this list are **actively recruiting** at one or more locations. Most studies in this list **accept healthy volunteers** with the exception of any studies missing a 'Y' in the Healthy Volunteers column. Those studies may or may not be ac

#74 Clinical Trials updated on 2021-07-22 All 74 studies in this list are **actively recruiting** at one or more locations. Most studies in this list **accept healthy volunteers** with the exception of any studies missing a 'Y' in the Healthy Volunteers column. Those studies may or may not be acce

Here are the links to the two abstracts in NEJM: [Alirocumab abstract](http://www.nejm.org/doi/full/10.1056/NEJMoa1501031) [Evolocumab abstract](http://www.nejm.org/doi/full/10.1056/NEJMoa1500858) I saw the evolocumab story on NBC Nightly News last night, and you know if I saw it, thousands upon tho

Does anyone know of any studied benefit in switching between evolocumab and alirocumab? If you’ve heard of/read any articles, please point me in that direction as well. TIA

# Enlicitid: Erster oraler PCSK9-Inhibitor – Game-Changer für Cholesterin-Therapie? Auf der AHA-Jahrestagung in New Orleans wurden gerade die Phase-3-Daten zu **Enlicitid (Enlicitide Decanoate, MK-0616)** von Merck/MSD vorgestellt. Falls ihr es nicht mitbekommen habt: Das könnte ein ziemlicher Durch

Hi all, Posting on behalf of my mom (F55). She has familial cholesterol and is unable to take statin meds (due to adverse reaction that effects her muscles) so she was put on rapatha injections that are done every 2 weeks. This is the only option we had in Canada and she was having significant side

​ Some of you may remember me from [This Post](https://www.reddit.com/r/wallstreetbets/comments/dv83sb/arwr_will_be_the_next_top_pharmaceutical_company/?utm_source=share&utm_medium=web2x) where I talked about ARWR when it was sitting around $40 before it broke out and hit an ATH of $7

**47M with CAC 743** – Looking for Perspective I’m a 47-year-old male who recently had a coronary artery calcium (CAC) score of 743.9 (Agatston), which puts me >90th percentile for my age/sex. # CAC Breakdown: * Left Main: 146.0 * LAD: 171.5 * LCx: 237.1 * RCA: 189.4 * PDA: 0 Report impression:

**ALNY** ALNY is our top pick for 2022 as it nears a key inflection point: APOLLO-B data of patisiran in TTR-CM (mid- 22). This is set up for success given precedent cardiac subset data from TTR-PN trials. We model $2B+ sales for patisiran/vutrisiran in TTR-CM achievable given current $2B sales of

I have a stent and my numbers are not ideal LDL hovers between 90-110. However, HDL is 70 and Tryglicerides are very good (38 last time I checked). I take Crestor 20 mg. With life style and diet this is the best I can get. The doctor pushes me to do something to get LDL under 70. Here's where I stan

This is an automatic summary, [original](http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news_17-3-2017-14-40-10) reduced by 78%. ***** > The first in a new class of gene-silencing drugs, known as inclisiran, has halved cholesterol levels in patients at risk of cardiovas